4-乙酰氧基-4'-甲氧基-1,1'-联苯 | 114412-46-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-乙酰氧基-4'-甲氧基-1,1'-联苯
• 英文名称: 4-acetoxy-4'-methoxybiphenyl
• 英文别名: 4-acetoxy-4'-methoxy-1,1'-biphenyl；4-methoxy-4'-acetoxybiphenyl；Essigsaeure-(4-methoxy-biphenylyl-(4)-ester)；(4'-Methoxy-biphenylyl-(4))-acetat；[4-(4-methoxyphenyl)phenyl] acetate
• CAS: 114412-46-3
• 化学式: C₁₅H₁₄O₃
• 分子量: 242.274
• InChiKey: HWBRFSLHIGWEHJ-UHFFFAOYSA-N

物化性质

• 熔点：
  101 °C
• 沸点：
  369.3±35.0 °C(Predicted)
• 密度：
  1.119±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  18
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.13
• 拓扑面积：
  35.5
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-乙酰氧基-4'-甲氧基-1,1'-联苯 在 氢氧化钾 、 水 作用下， 生成 4-羟基-4-甲氧基联二苯
  参考文献：
  名称：

  Biaryl Construction via Ni-Catalyzed C−O Activation of Phenolic Carboxylates

  摘要：

  Biaryl scaffolds were constructed via Ni-catalyzed aryl C-O activation by avoiding cleavage of the more reactive acyl C-O bond aryl carboxylates. Now aryl esters, in general, can be successfully employed in cross-coupling reactions for the first time. The substrate scope and synthetic utility of the chemistry were demonstrated by the syntheses of more than 40 biaryls and by constructing complex organic molecules. Water was observed to play an important role in facilitating this transformation.

  DOI：

  10.1021/ja8056503
• 作为产物：
  描述：

  1-(4-甲氧基-联苯-4-基)-乙酮 在 sodium perborate tetrahydrate 作用下， 生成 4-乙酰氧基-4'-甲氧基-1,1'-联苯
  参考文献：
  名称：

  Biaryl Construction via Ni-Catalyzed C−O Activation of Phenolic Carboxylates

  摘要：

  Biaryl scaffolds were constructed via Ni-catalyzed aryl C-O activation by avoiding cleavage of the more reactive acyl C-O bond aryl carboxylates. Now aryl esters, in general, can be successfully employed in cross-coupling reactions for the first time. The substrate scope and synthetic utility of the chemistry were demonstrated by the syntheses of more than 40 biaryls and by constructing complex organic molecules. Water was observed to play an important role in facilitating this transformation.

  DOI：

  10.1021/ja8056503

文献信息

• Substituted benzoylbenzene-, biphenyl- and 2-oxazole-alkanoic acid
  申请人：American Home Products Corporation

  公开号：US05218124A1

  公开（公告）日：1993-06-08

  There are disclosed compounds of the formula A(CH.sub.2).sub.n O--B wherein A is a group having the formula ##STR1## wherein X is --N-- or ##STR2## Z is ##STR3## R.sup.1 is hydrogen, lower alkyl or phenyl; R.sup.2 is hydrogen or lower alkyl; or R.sup.1 and R.sup.2 taken together form a benzene ring, with the proviso that when X is --N--, Z is other than ##STR4## R.sup.3 is hydrogen or lower alkyl; n is 1-2; B is ##STR5## wherein Y is OR.sup.5 or N(OH)R.sup.8 ; R.sup.4 and R.sup.5 are each, independently, hydrogen or lower alkyl; R.sup.6 is hydrogen, halo or nitro; R.sup.7 is ##STR6## R.sup.8 is lower alkyl; m is 0-3; and the pharmacologically acceptable salts thereof, and their use in the treatment of inflammatory conditions, such as rheumatoid arthritis, ulcerative colitis, psoriasis and other immediate hypersensitivity reactions; in the treatment of leukotriene-mediated naso-bronchial obstructive air-passageway conditions, such as allergic rhinitis, allergic bronchial asthma and the like; and as gastric cytoprotective agents.

  已披露的化合物的化学式为A(CH.sub.2).sub.n O--B，其中A是具有以下化学式的基团 ##STR1## 其中X为--N--或##STR2## Z为##STR3## R.sup.1为氢、低碳烷基或苯基；R.sup.2为氢或低碳烷基；或R.sup.1和R.sup.2一起形成苯环，条件是当X为--N--时，Z不是##STR4## R.sup.3为氢或低碳烷基；n为1-2；B为##STR5## 其中Y为OR.sup.5或N(OH)R.sup.8；R.sup.4和R.sup.5分别独立地为氢或低碳烷基；R.sup.6为氢、卤素或硝基；R.sup.7为##STR6## R.sup.8为低碳烷基；m为0-3；以及其药理学上可接受的盐，以及它们在治疗炎症性疾病，如类风湿关节炎、溃疡性结肠炎、银屑病和其他即时过敏反应；在治疗白三烯介导的鼻支气管阻塞性通气道疾病，如过敏性鼻炎、过敏性支气管哮喘等；以及作为胃黏膜保护剂的用途。
• Substituted benzoylbenzene-, biphenyl- and 2-oxazole- alkanoic acid
  申请人：American Home Products Corporation

  公开号：US05364944A1

  公开（公告）日：1994-11-15

  There are disclosed substituted benzoylbenzene-, biphenyl- and 2-oxazole- alkanoic acid derivatives and the pharmacologically acceptable salts thereof as inhibitors of PLA.sub.2 and lipoxygenase, and their use in the treatment of inflammatory conditions, such as rheumatoid arthritis, ulcerative colitis, psoriasis and other immediate hypersensitivity reactions; in the treatment of leukotriene-mediated naso-bronchial obstructive air-passageway conditions, such as allergic rhinitis, allergic bronchial asthma and the like; and as gastric cytoprotective agents.

  所披露的替代苯甲酰苯、联苯和2-噁唑-烷基酸衍生物及其药理学上可接受的盐被用作 PLA.sub.2 和脂氧合酶的抑制剂，并用于治疗炎症性疾病，如类风湿性关节炎、溃疡性结肠炎、银屑病和其他即时过敏反应；用于治疗白三烯介导的鼻支气管阻塞症状，如过敏性鼻炎、过敏性支气管哮喘等；以及作为胃粘膜保护剂。
• Reversion of Alignment Direction in the Thermally Enhanced Photoorientation of Photo-Cross-Linkable Polymer Liquid Crystal Films
  作者：Nobuhiro Kawatsuki、Kohei Goto、Tetsuro Kawakami、Tohei Yamamoto

  DOI：10.1021/ma011439u

  日期：2002.1.1

  anisotropy of the films as a result of an axis-selective photoreaction of the side groups. The direction of the thermally enhanced reorientation is dependent on the degree of photoreaction and the distribution of photoproducts, while the induced orientational order in both directions, S, was larger than 0.5. The distribution of photoproducts in PLC films has been analyzed to elucidate their contribution

  在用4-甲氧基肉桂酰氧基联苯侧基取代的新型聚甲基丙烯酸酯液晶（PLC）薄膜中，首次观察到介晶基团的面内取向方向的反转。通过用线偏振紫外线（LPUV）照射并随后进行退火来产生回复。由于侧基的轴选择性光反应，用LPUV光照射会引起薄膜的负光学各向异性。热增强重取向的方向取决于光反应的程度和光产物的分布，而在两个方向上诱导的取向顺序S，大于0.5。已经分析了光产物在PLC胶片中的分布，以阐明它们对热增强的重取向行为的贡献。最初在光反应时，观察到光诱导的负光学各向异性的热增强。然而，当光二聚化度为15％或更大时，发现热增强的重新取向的方向平行于偏振方向（E）的LPUV光。结论是，少量的光产物以与具有偶氮苯侧基的PLC相同的方式在光诱导的负光学各向异性的热放大中起作用。相反，光二聚的介晶基团通过退火产生了取向方向的反转并增强了膜的正光学各向异性。
• Alpha-methylcinnamic acid ester derivative and liquid crystal composition
  申请人：Mitsubishi Rayon Company Ltd.

  公开号：US04751018A1

  公开（公告）日：1988-06-14

  Disclosed is an .alpha.-methylcinnamic acid ester derivative represented by the formula: ##STR1## wherein n is an integer of from 5 to 18, R.sub.1 represents an optically active group of the formula ##STR2## in which m is an integer of from 1 to 5 and *C represents an asymmetric carbon atom, and R.sub.2 represents ##STR3## The .alpha.-methylcinnamic acid ester derivative is valuable as a ferroelectric liquid crystal or an additive to a ferroelectric liquid crystal.

  本发明涉及一种α-甲基肉桂酸酯衍生物，其表示为以下公式：##STR1## 其中n为5至18的整数，R1表示具有以下公式的手性活性基团：##STR2## 其中m为1至5的整数，*C表示不对称碳原子，R2表示##STR3## 该α-甲基肉桂酸酯衍生物可作为铁电液晶或铁电液晶的添加剂具有价值。
• TISSUE FACTOR PRODUCTION INHIBITOR
  申请人：Sankyo Company, Limited

  公开号：EP1764075A1

  公开（公告）日：2007-03-21

  A medicament which has an activity of inhibiting production of tissue factor and comprises an LXR ligand as an active ingredient; and a medicament for treatment and/or prophylaxis of vascular restenosis following angioplasty, endarterectomy, percutaneous transluminal coronary angioplasty (PTCA) or stent implantation, or treatment and/or prophylaxis of blood coagulation diseases, diseases induced by platelet aggregation including stable or unstable angina pectoris, cardiovascular and cerebrovascular diseases including thromboembolism formation diseases accompanying diabetes, rethrombosis following thrombolysis, cerebral ischemic attack, infarction, stroke, ischemia-derived dementia, peripheral artery disease, thromboembolism formation diseases during use of an aorta-coronary artery bypass, glomerulosclerosis, renal embolism, tumor or cancer metastasis, which comprises an LXR ligand as an active ingredient.

  一种具有抑制组织因子生成活性的药物，其活性成分包括一种 LXR 配体；用于治疗和/或预防血管成形术、动脉内膜切除术、经皮腔内冠状动脉成形术（PTCA）或支架植入术后的血管再狭窄，或治疗和/或预防血液凝固疾病、血小板聚集诱发的疾病（包括稳定型或不稳定型心绞痛）的药物、心脑血管疾病，包括伴随糖尿病的血栓栓塞形成疾病、溶栓后的再血栓形成、脑缺血发作、脑梗塞、中风、缺血性痴呆、外周动脉疾病、使用主动脉-冠状动脉搭桥过程中的血栓栓塞形成疾病、肾小球硬化、肾栓塞、肿瘤或癌症转移，其活性成分包括 LXR 配体。